We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+6.74%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$108M
AUM Growth
+$6.52M
Cap. Flow
+$3.31M
Cap. Flow %
3.06%
Top 10 Hldgs %
50.36%
Holding
47
New
11
Increased
13
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$5.38M
2
DVA icon
DaVita
DVA
+$5.19M
3
INSM icon
Insmed
INSM
+$3.64M
4
INCY icon
Incyte
INCY
+$3.39M
5
FOLD
Amicus Therapeutics
FOLD
+$3.16M

Top Sells

Rank Stock Value
1
OPTN
OptiNose
OPTN
+$9.4M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.22M
3
EXAS
Exact Sciences
EXAS
+$5.08M
4
DGX icon
Quest Diagnostics
DGX
+$2.7M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.17M

Sector Composition

Rank Sector Weight
1 Healthcare 86.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
1
PTC Therapeutics
PTCT
$6.29B
$8.13M 7.51%
173,010
-32,021
-16% -$1.32M
INSM icon
2
Insmed
INSM
$22.7B
$7.28M 6.73%
360,182
+161,381
+81% +$3.64M
PTLA
3
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$6.71M 6.2%
251,881
+164,765
+189% +$5.38M
ACHC icon
4
Acadia Healthcare
ACHC
$2.99B
$6.57M 6.07%
186,631
+58,391
+46% +$2.33M
DVA icon
5
DaVita
DVA
$15.2B
$5.26M 4.86%
+73,471
New +$5.19M
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
$4.49M 4.15%
72,970
+23,214
+47% +$1.49M
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
$4.33M 4%
358,191
+226,031
+171% +$3.16M
UNH icon
8
UnitedHealth
UNH
$379B
$4.08M 3.77%
15,344
+892
+6% +$232K
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.93M 3.63%
103,449
+54,094
+110% +$2.4M
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$16B
$3.72M 3.44%
22,144
-7,481
-25% -$1.29M
CNC icon
11
Centene
CNC
$31.6B
$3.6M 3.33%
49,724
-28,392
-36% -$1.97M
INCY icon
12
Incyte
INCY
$23.7B
$3.41M 3.15%
+49,420
New +$3.39M
ANAB icon
13
AnaptysBio
ANAB
$1.59B
$3.31M 3.06%
33,211
-7,507
-18% -$623K
PFE icon
14
Pfizer
PFE
$141B
$3.01M 2.78%
+72,000
New +$2.77M
NTRA icon
15
Natera
NTRA
$37B
$2.98M 2.75%
124,517
+5,648
+5% +$136K
NBIX icon
16
Neurocrine Biosciences
NBIX
$17.7B
$2.84M 2.63%
23,133
-3,777
-14% -$429K
CVS icon
17
CVS Health
CVS
$137B
$2.82M 2.61%
+35,870
New +$2.56M
OSUR icon
18
OraSure Technologies
OSUR
$273M
$2.77M 2.56%
+179,496
New +$2.94M
VRTX icon
19
Vertex Pharmaceuticals
VRTX
$122B
$2.44M 2.25%
12,650
-40,558
-76% -$7.22M
SRPT icon
20
Sarepta Therapeutics
SRPT
$1.68B
$2.34M 2.16%
14,508
+3,259
+29% +$446K
XLRN
21
DELISTED
Acceleron Pharma
XLRN
$2.28M 2.11%
39,912
+17,354
+77% +$853K
NCNA
22
NuCana
NCNA
$5.24M
$2.18M 2.01%
17
+7
+70% +$825K
VRAY
23
DELISTED
ViewRay, Inc.
VRAY
$2.1M 1.94%
223,885
-166,683
-43% -$1.64M
PEN icon
24
Penumbra
PEN
$12.6B
$1.97M 1.82%
+13,187
New +$1.85M
IONS icon
25
Ionis Pharmaceuticals
IONS
$9.25B
$1.91M 1.76%
+37,021
New +$1.74M
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Asymmetry Capital Management held 47 positions worth $108M, up 6.4% from $102M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Asymmetry Capital Management deployed $3.31M of net new capital in Q3 2018, opening 11 new positions and adding to 13 existing holdings. Its largest new stake was DaVita: 73,471 shares worth $5.26M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 90% a quarter earlier.

On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $7.22M trimmed.

  • Asymmetry Capital Management's largest Q3 2018 buy was DaVita: 73,471 shares worth $5.26M.
  • Asymmetry Capital Management added most to Portola Pharmaceuticals, Inc. in Q3 2018, an estimated $5.38M increase.
  • Asymmetry Capital Management's biggest Q3 2018 reduction was Vertex Pharmaceuticals, cutting an estimated $7.22M.
  • Asymmetry Capital Management fully exited OptiNose in Q3 2018, selling an estimated $9.4M.
  • Asymmetry Capital Management's ten largest holdings make up 50% of its $108M portfolio in Q3 2018.
  • Asymmetry Capital Management opened 11 new positions and closed 12 in Q3 2018.
  • Asymmetry Capital Management's portfolio value rose 6.4% quarter-over-quarter to $108M.

Based on Asymmetry Capital Management's 13F filing for Q3 2018, filed 8 Nov 2018.